Pfizer might buy BMS for $130bn – but should it?
Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.
Clovis and BMS research small molecule and antibody combination.
The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
NHS initially denied late writer immunotherapy.
Roche’s PD-L1 drug has generated impressive data in second line lung cancer